Recent advances in the treatment and delivery system of diabetic retinopathy

• Published in: Frontiers in endocrinology (Lausanne) 2024-02, Vol.15, p.1347864-1347864
• Main Authors: Wang, Zhiyi, Zhang, Ningzhi, Lin, Pei, Xing, Yiqiao, Yang, Ning
• Format: Article
• Language: English
• Subjects: anti-VEGF drugs; diabetic retinopathy; drug-delivery system; Endocrinology; gene therapy; laser treatment; nanotechnology
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2024.1347864

Diabetic retinopathy (DR) is a highly tissue-specific neurovascular complication of type 1 and type 2 diabetes mellitus and is among the leading causes of blindness worldwide. Pathophysiological changes in DR encompass neurodegeneration, inflammation, and oxidative stress. Current treatments for DR, including anti-vascular endothelial growth factor, steroids, laser photocoagulation, and vitrectomy have limitations and adverse reactions, necessitating the exploration of novel treatment strategies. This review aims to summarize the current pathophysiology, therapeutic approaches, and available drug-delivery methods for treating DR, and discuss their respective development potentials. Recent research indicates the efficacy of novel receptor inhibitors and agonists, such as aldose reductase inhibitors, angiotensin-converting enzyme inhibitors, peroxisome proliferator-activated receptor alpha agonists, and novel drugs in delaying DR. Furthermore, with continuous advancements in nanotechnology, a new form of drug delivery has been developed that can address certain limitations of clinical drug therapy, such as low solubility and poor penetration. This review serves as a theoretical foundation for future research on DR treatment. While highlighting promising therapeutic targets, it underscores the need for continuous exploration to enhance our understanding of DR pathogenesis. The limitations of current treatments and the potential for future advancements emphasize the importance of ongoing research in this field.